New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents.

Most of the anticancer chemotherapeutic drugs that are broadly and successfully used today are DNA-damaging agents. Targeting of DNA has been proven to cause relatively potent and selective destruction of tumor cells. However, the clinical potential of DNA-damaging agents is limited by the adverse side effects and increased risk of secondary cancers that are consequences of the agents' genotoxicity. In this review, we present evidence that those agents capable of targeting DNA without inducing DNA damage would not be limited in these ways, and may be as potent as DNA-damaging agents in the killing of tumor cells. We use as an example literature data and our own research of the well-known antimalarial drug quinacrine, which binds to DNA without inducing DNA damage, yet modulates a number of cellular pathways that impact tumor cell survival.

[1]  Ronald D Snyder,et al.  Evaluation of the clastogenic, DNA intercalative, and topoisomerase II‐interactive properties of bioflavonoids in Chinese hamster V79 cells , 2002, Environmental and molecular mutagenesis.

[2]  I. Lasnitzki,et al.  The Effect of Acridine Derivatives on Growth and Mitoses of Cells In Vitro , 1948, British Journal of Cancer.

[3]  K. Bielawski,et al.  Small‐Molecule based Delivery Systems for Alkylating Antineoplastic Compounds , 2008, ChemMedChem.

[4]  S. Metz.  Exogenous Arachidonic Acid Promotes Insulin Release From Intact or Permeabilized Rat Islets by Dual Mechanisms: Putative Activation of Ca2+ Mobilization and Protein Kinase C , 1988, Diabetes.

[5]  M. Tisdale,et al.  Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes , 2003, British Journal of Cancer.

[6]  G. S. Kumar,et al.  DNA intercalation by quinacrine and methylene blue: a comparative binding and thermodynamic characterization study. , 2008, DNA and cell biology.

[7]  A. Freedman,et al.  Mepacrine and rheumatoid arthritis. , 1952, Lancet.

[8]  W. Denny,et al.  Non-covalent ligand/DNA interactions: minor groove binding agents. , 2007, Mutation research.

[9]  W. Denny,et al.  Genotoxicity of non-covalent interactions: DNA intercalators. , 2007, Mutation research.

[10]  J. Whelan,et al.  Distamycin prolongs E-selectin expression by interacting with a specific NF-kappaB-HMG-I(Y) binding site in the promoter. , 1997, Nucleic acids research.

[11]  M. Nishibori,et al.  Two polymorphic forms of human histamine methyltransferase: structural, thermal, and kinetic comparisons. , 2001, Structure.

[12]  Louis S. Goodman,et al.  The Pharmacological Basis of Therapeutics. , 1941 .

[13]  M. V. Van Beek,et al.  Antimalarials , 2001, Dermatologic clinics.

[14]  M. Crouch,et al.  Mepacrine inhibition of bradykinin-induced contractions of the rabbit ear vein , 1981, Agents and Actions.

[15]  E. Squires,et al.  Role of aldehyde oxidase in the hepatic in vitro metabolism of 3-methylindole in pigs. , 2000, Journal of agricultural and food chemistry.

[16]  J. McAnulty,et al.  The effect of quinacrine on oxidative stress in kidney tissue stored at low temperature after warm ischemic injury. , 1999, Cryobiology.

[17]  O. Berg,et al.  Interfacial catalysis by phospholipase A2: dissociation constants for calcium, substrate, products, and competitive inhibitors. , 1991, Biochemistry.

[18]  K. Renton,et al.  Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents. , 1976, Biochemical and biophysical research communications.

[19]  J. Nagai,et al.  Inhibition of oxidative hemolysis and lipid peroxidation by mepacrine. , 1981, Journal of biochemistry.

[20]  P. Kinnunen,et al.  Binding of quinacrine to acidic phospholipids and pancreatic phospholipase A2. Effects on the catalytic activity of the enzyme. , 1998, Biochemistry.

[21]  J. Lindenmayer,et al.  Toxic psychosis following use of quinacrine. , 1981, The Journal of clinical psychiatry.

[22]  M. Wolter,et al.  Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. , 1999, Cancer research.

[23]  H. Heimpel,et al.  Drug-induced aplastic anaemia: clinical aspects. , 1980, Clinics in haematology.

[24]  M. Tariq,et al.  Effect of quinacrine, a phospholipase A2 inhibitor on stress and chemically induced gastroduodenal ulcers. , 1997, Digestion.

[25]  Malra C. Treece.  An A is an A is an A is an E. , 1976 .

[26]  F. Bushman,et al.  HIV-1 cDNA Integration: Requirement of HMG I(Y) Protein for Function of Preintegration Complexes In Vitro , 1997, Cell.

[27]  T. Sourkes,et al.  Inhibition of diamine oxidase by antimalarial drugs , 1980, Agents and Actions.

[28]  M. Bianchi,et al.  HMGB proteins and gene expression. , 2003, Current opinion in genetics & development.

[29]  A. Rossi,et al.  Targeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. , 2006, Cancer research.

[30]  C. Piper,et al.  An E coli microsuspension assay for the detection of DNA damage induced by direct-acting agents and promutagens. , 1981, Environmental mutagenesis.

[31]  N. Flamand,et al.  Histamine‐induced inhibition of leukotriene biosynthesis in human neutrophils: involvement of the H2 receptor and cAMP , 2004, British journal of pharmacology.

[32]  P. Gray,et al.  DNA minor groove binders: back in the groove. , 2009, Cancer treatment reviews.

[33]  Stephen Neidle,et al.  Protein and drug interactions in the minor groove of DNA. , 2002, Nucleic acids research.

[34]  F. Elequin,et al.  Morphological transformation, DNA strand separation, and antinucleoside immunoreactivity following exposure of cells to intercalating drugs. , 1982, Molecular pharmacology.

[35]  Hycanthone and its congeners as bacterial mutagens , 1975, Journal of bacteriology.

[36]  T. Steitz,et al.  Crystal structure of a CAP-DNA complex: the DNA is bent by 90 degrees , 1991, Science.

[37]  J. Burch,et al.  Direct interaction of mepacrine with erythrocyte and platelet membrane phospholipid. , 1982, The Journal of biological chemistry.

[38]  A M Gronenborn,et al.  Minor groove-binding architectural proteins: structure, function, and DNA recognition. , 1998, Annual review of biophysics and biomolecular structure.

[39]  M. Schumacher,et al.  Crystal structure of LacI member, PurR, bound to DNA: minor groove binding by alpha helices. , 1994, Science.

[40]  R. Carr,et al.  Ocular toxicity of antimalarial drugs. Long-term follow-up. , 1968, American journal of ophthalmology.

[41]  M. Aslanoglu,et al.  Voltammetric studies of the interaction of quinacrine with DNA , 2004, Analytical and bioanalytical chemistry.

[42]  A. Krishnaja,et al.  Quinacrine dihydrochloride, the non-surgical female sterilant induces dicentrics, rings, and marker chromosomes in human peripheral blood lymphocytes treated in vitro: a preliminary report. , 2000, Mutation research.

[43]  W. J. Morginson.  [Lupus erythematosus]. , 1960, Revista medica hondurena.

[44]  R. Tsushima,et al.  Functional and electrophysiological effects of quinacrine on the response of ventricular tissues to hypoxia and reoxygenation. , 1989, Canadian Journal of Physiology and Pharmacology.

[45]  J. Morisset,et al.  Endogenous Arachidonic Acid Release and Pancreatic Amylase Secretion , 1997, Pancreas.

[46]  O. Sapp.  TOXIC PSYCHOSIS DUE TO QUINARCRINE AND CHLOROQUINE. , 1964, JAMA.

[47]  W. Wilson,et al.  Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs. , 1989, European journal of cancer & clinical oncology.

[48]  R. Harris,et al.  A potential mechanism for proximal tubule angiotensin II-mediated sodium flux associated with receptor-mediated endocytosis and arachidonic acid release. , 1996, Kidney international. Supplement.

[49]  M. Bianchi,et al.  HMG proteins: dynamic players in gene regulation and differentiation. , 2005, Current opinion in genetics & development.

[50]  R. Dickerson,et al.  How proteins recognize the TATA box. , 1996, Journal of molecular biology.

[51]  T. Otamiri.  Influence of quinacrine on plasma malondialdehyde after small intestinal ischemia and reperfusion. , 1988, Circulatory shock.

[52]  E. Kobrinsky,et al.  Ca2+-antagonistic properties of phospholipase A2 inhibitors, mepacrine and chloroquine. , 1989, General physiology and biophysics.

[53]  M. K. Bach.  Reduction in the frequency of mutation to resistance to cytarabine in L1210 murine leukemic cells by treatment with quinacrine hydrochloride. , 1969, Cancer research.

[54]  M. Chiariello,et al.  Reduction in infarct size by the phospholipase inhibitor quinacrine in dogs with coronary artery occlusion. , 1990, American heart journal.

[55]  L. Chacón-García,et al.  The search of DNA-intercalators as antitumoral drugs: what it worked and what did not work. , 2005, Current medicinal chemistry.

[56]  C. Ioannides,et al.  Inhibition of rat hepatic mixed function oxidases by antimalarial drugs: selectivity for cytochromes P-450 and P-448. , 1984, Chemico-biological interactions.

[57]  L. Strekowski,,et al.  Noncovalent interactions with DNA: an overview. , 2007, Mutation research.

[58]  R. Tibbetts,et al.  Molecular Linkage Between the Kinase ATM and NF-κB Signaling in Response to Genotoxic Stimuli , 2006, Science.

[59]  R. Snyder,et al.  Toward a greater appreciation of noncovalent chemical/DNA interactions: Application of biological and computational approaches , 2005, Environmental and molecular mutagenesis.

[60]  B. Gatto,et al.  Design, synthesis, and biological properties of new bis(acridine-4-carboxamides) as anticancer agents. , 2003, Journal of medicinal chemistry.

[61]  G. Chang,et al.  Crystal Structure of the Lactose Operon Repressor and Its Complexes with DNA and Inducer , 1996, Science.

[62]  S. Borowitz,et al.  The role of phospholipase A activity in rat liver microsomal lipid peroxidation. , 1987, The Journal of biological chemistry.

[63]  A. Albert.  The acridines. Their preparation, physical, chemical and biological properties and uses. , 1951 .

[64]  F. Thomson,et al.  Differential involvement of phospholipase A2 in phorbol ester-induced luteinizing hormone and growth hormone release from rat anterior pituitary tissue , 1993, Molecular and Cellular Endocrinology.

[65]  D. Reinberg,et al.  de FACTo Nucleosome Dynamics* , 2006, Journal of Biological Chemistry.

[66]  P. Chumakov,et al.  p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism , 2004, Cancer Research.

[67]  M. Jansen,et al.  Advances in DNA-ligands with groove binding, intercalating and/or alkylating activity: chemistry, DNA-binding and biology. , 2005, Current medicinal chemistry.

[68]  R. Fraser.  The structure of deoxyribose nucleic acid. , 2004, Journal of structural biology.

[69]  R. Berliner,et al.  The Pharmacological Basis for the Rational Use of Atabrine in the Treatment of Malaria. , 1944 .

[70]  T. Cook,et al.  Antibacterial Nitroacridine, Nitroakridin 3582: Binding to Nucleic Acids In Vitro and Effects on Selected Cell-Free Model Systems of Macromolecular Biosynthesis , 1971, Journal of bacteriology.

[71]  H L Pearce,et al.  Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. , 1988, Molecular pharmacology.

[72]  I. Hickson,et al.  Potent inhibition of werner and bloom helicases by DNA minor groove binding drugs. , 2000, Nucleic acids research.

[73]  S. Stohs,et al.  The possible role of phospholipase A2 in hepatic microsomal lipid peroxidation induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats , 1991, Archives of environmental contamination and toxicology.

[74]  J. Phillis,et al.  The phospholipase A2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion , 1997, Brain Research.

[75]  C. Croce,et al.  Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice , 2005, Nature Medicine.

[76]  M. Kruhøffer,et al.  Identification of the Genes Up- and Down-Regulated by the High Mobility Group A1 (HMGA1) Proteins , 2004, Cancer Research.

[77]  G. J. Blackwell,et al.  THE DISTRIBUTION AND METABOLISM OF ARACHIDONIC ACID IN RABBIT PLATELETS DURING AGGREGATION AND ITS MODIFICATION BY DRUGS , 1977, British journal of pharmacology.

[78]  D. Sokal,et al.  A One-Year Neonatal Mouse Carcinogenesis Study of Quinacrine Dihydrochloride , 2006, International journal of toxicology.

[79]  K. Khalili,et al.  Multiple roles for Pur-α in cellular and viral regulation , 2009, Cell cycle.

[80]  A. Canals,et al.  DNA-binding drugs caught in action: the latest 3D pictures of drug-DNA complexes. , 2009, Dalton transactions.

[81]  M. Wolfe.  The treatment of intestinal protozoan infections. , 1982, The Medical clinics of North America.

[82]  J. Whelan,et al.  expression of the E-selectin promoter . protein I ( Y ) , is essential for cytokine-induced complexes , mediated by high-mobility-group Cooperativity between two NF-kappa B , 2022 .

[83]  M. Shannon,et al.  The Human IL-2 Gene Promoter Can Assemble a Positioned Nucleosome That Becomes Remodeled Upon T Cell Activation1 , 2002, The Journal of Immunology.

[84]  R. Reeves,et al.  Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells , 2004, Oncogene.

[85]  T. Hour,et al.  A new mutagenicity assay method for frameshift mutagens based on deleting or inserting a guanosine nucleotide in the beta-lactamase gene. , 1995, Mutagenesis.

[86]  Y. Kohjimoto,et al.  Role of phospholipase A2 in the cytotoxic effects of oxalate in cultured renal epithelial cells. , 1999, Kidney international.

[87]  D. Kahne.  Strategies for the design of minor groove binders: a re-evaluation based on the emergence of site-selective carbohydrate binders. , 1995, Chemistry & biology.

[88]  P. Upcroft,et al.  Drug Targets and Mechanisms of Resistance in the Anaerobic Protozoa , 2001, Clinical Microbiology Reviews.

[89]  L. Garey,et al.  Induction of astrocytic cytoplasmic phospholipase A2 and neuronal death after intracerebroventricular carrageenan injection, and neuroprotective effects of quinacrine , 2003, Experimental Neurology.

[90]  T. Maniatis,et al.  A striking similarity in the organization of the E-selectin and beta interferon gene promoters , 1994, Molecular and cellular biology.

[91]  Ronald D Snyder,et al.  Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay. , 2002, Mutation research.

[92]  A. Travers,et al.  HMG1 and 2, and related 'architectural' DNA-binding proteins. , 2001, Trends in biochemical sciences.

[93]  P. Epstein,et al.  Local anesthetics, mepacrine, and propranolol are antagonists of calmodulin. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[94]  R. Marcos,et al.  Testing of chloroquine and quinacrine for mutagenicity in Drosophila melanogaster. , 1985, Mutation research.

[95]  V. Kinzel,et al.  Mobilization of diacylglycerol in intact HeLa cells by exogenous phospholipase C from Cl. perfringens is accompanied by release of fatty acids including arachidonic acid. , 1992, Biochimica et biophysica acta.

[96]  V. O. Wagner,et al.  Re-evaluation of the mutagenic potential of quinacrine dihydrochloride dihydrate. , 2001, Mutation research.

[97]  N. Leone,et al.  Aplastic anemia induced by quinacrine. , 1965, Archives of dermatology.

[98]  A. Gudkov,et al.  Anti-malaria drug blocks proteotoxic stress response: Anti-cancer implications , 2009, Cell cycle.

[99]  R. L. Zuehlke,et al.  Antimalarial Therapy for Lupus Erythematosus: An Apparent Advantage of Quinacrine , 1981, International journal of dermatology.

[100]  M. D. Young,et al.  The efficacy of chloroquine, quinacrine, quinine and totaquine in the treatment of Plasmodium malariae infections (quartan malaria). , 1948, The American journal of tropical medicine and hygiene.

[101]  F. Crick,et al.  Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid , 1953, Nature.

[102]  J. V. Tongeren,et al.  GIARDIASIS , 1977, The Lancet.

[103]  E. Kessel.  100 000 quinacrine sterilizations , 1996, Advances in Contraception.

[104]  R. Reneman,et al.  Effects of nicotinic acid and mepacrine on fatty acid accumulation and myocardial damage during ischemia and reperfusion. , 1990, Journal of molecular and cellular cardiology.

[105]  J. Connor,et al.  Quinacrine attenuates increases in divalent metal transporter-1 and iron levels in the rat hippocampus, after kainate-induced neuronal injury , 2003, Neuroscience.

[106]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[107]  A. Bartoszek,et al.  DNA damage in HeLa s3 cells by an antitumor drug Ledakrin and other antitumor 1-nitro-9-aminoacridines. , 1984, Chemico-biological interactions.

[108]  Jian Jian Li,et al.  ATM-NF-κB Connection as a Target for Tumor Radiosensitization , 2007 .

[109]  T. Imazawa,et al.  Enhancing Effects of Quinacrine on Development of Hepatopancreatic Lesions in N‐Nitrosobis(2‐oxopropyl)amine‐initiated Hamsters , 1998, Japanese journal of cancer research : Gann.

[110]  W. Denny.  DNA-intercalating ligands as anti-cancer drugs: prospects for future design. , 1989, Anti-cancer drug design.

[111]  R. Mitchel,et al.  A Lower Dose Threshold for the In Vivo Protective Adaptive Response to Radiation. Tumorigenesis in Chronically Exposed Normal and Trp53 Heterozygous C57BL/6 Mice , 2008, Radiation research.

[112]  A. Andreoni,et al.  DNA‐ligand Binding Mode Discrimination by Characterizing Fluorescence Resonance Energy Transfer Through Lifetime Measurements with Picosecond Resolution , 2007, Photochemistry and photobiology.

[113]  J. Bourdon,et al.  p53 and its isoforms in cancer , 2007, British Journal of Cancer.

[114]  C. Klaassen,et al.  Effects of phospholipase A2 inhibitors on diethyl maleate-induced lipid peroxidation and cellular injury in isolated rat hepatocytes. , 1982, Journal of toxicology and environmental health.

[115]  Ronald D Snyder,et al.  Assessment of atypical DNA intercalating agents in biological and in silico systems. , 2007, Mutation research.

[116]  J. Castro,et al.  Late preventive effects of quinacrine on carbon tetrachloride induced liver necrosis , 2005, Archives of Toxicology.

[117]  J. Piette,et al.  NF-κB activation by double-strand breaks , 2006 .

[118]  J. P. Smith,et al.  Studies on the mechanism of alteration by propranolol and mepacrine of the metabolism of phosphoinositides and other glycerolipids in the rabbit iris muscle. , 1983, Biochemical pharmacology.

[119]  I. Yamaguchi,et al.  Quinacrine-blocked desensitization of adrenoceptors after immobilization stress or repeated injection of isoproterenol in rats. , 1981, The Journal of pharmacology and experimental therapeutics.

[120]  A. Mantovani,et al.  Rapid induction of arachidonic acid release by monocyte chemotactic protein-1 and related chemokines. Role of Ca2+ influx, synergism with platelet-activating factor and significance for chemotaxis. , 1994, The Journal of biological chemistry.

[121]  R. L. Jones,et al.  Comparative viscometric analysis of the interaction of chloroquine and quinacrine with superhelical and sonicated DNA. , 1979, Biochimica et biophysica acta.

[122]  D. Wallace.  The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. , 1989, Seminars in arthritis and rheumatism.

[123]  T. Tetaz,et al.  Association of a phospholipase A2 (14-3-3 protein) with the platelet glycoprotein Ib-IX complex. , 1994, The Journal of biological chemistry.

[124]  F. Charmantray,et al.  Interest of acridine derivatives in the anticancer chemotherapy. , 2001, Current pharmaceutical design.

[125]  R. Shafer,et al.  Differential binding of the enantiomers of chloroquine and quinacrine to polynucleotides: Implications for stereoselective metabolism , 1993, Biopolymers.

[126]  E. Bohn,et al.  Effects of antimalarial drugs on phospholipase A and lysophospholipase activities in plasma membrane, mitochondrial, microsomal and cytosolic subcellular fractions of rat liver. , 1985, Biochimica et biophysica acta.

[127]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[128]  W. Muster,et al.  Genotoxicity of 17 gyrase- and four mammalian topoisomerase II-poisons in prokaryotic and eukaryotic test systems. , 1995, Mutagenesis.

[129]  K. Kohn,et al.  Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. , 1988, Cancer research.

[130]  K. Koike,et al.  Arachidonate stimulates prolactin release in vitro: a role for the fatty acid and its metabolites as intracellular regulator(s) in mammotrophs. , 1985, Endocrinology.

[131]  C Ramel,et al.  The induction of micronuclei by frameshift mutagens at the time of nucleus expulsion in mouse erythroblasts. , 1974, Mutation research.

[132]  M. G. Sevag.  PREVENTION OF THE EMERGENCE OF ANTIBIOTIC-RESISTANT STRAINS OF BACTERIA BY ATABRINE. , 1964, Archives of biochemistry and biophysics.

[133]  A. Lochner,et al.  Postcardioplegic Myocardial Recovery: Effects of Halothane, Nifedipine, HOE 694, and Quinacrine , 1998, Cardiovascular Drugs and Therapy.

[134]  Santa Jeremy Ono,et al.  IFN-γ gene expression is controlled by the architectural transcription factor HMGA1 , 2005 .

[135]  G. Emerole,et al.  Drug induced alterations in some rat hepatic microsomal components: a comparative study of four structurally different antimalarials. , 1985, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.

[136]  N. B. Atkin.  Y chromosomes and quinacrine fluorescence technique. , 1970, British medical journal.

[137]  T. Maniatis,et al.  Virus induction of human IFNβ gene expression requires the assembly of an enhanceosome , 1995, Cell.

[138]  R. L. Jones,et al.  The effect of ionic strength on DNA-ligand unwinding angles for acridine and quinoline derivatives. , 1980, Nucleic acids research.

[139]  V. Caiolfa,et al.  GR and HMGB1 interact only within chromatin and influence each other's residence time. , 2005, Molecular cell.

[140]  T. Graboys,et al.  Effect of a digitalis drug on ventricular premature beats. , 1977, The New England journal of medicine.

[141]  D. Reinberg,et al.  Tracking FACT and the RNA Polymerase II Elongation Complex Through Chromatin in Vivo , 2003, Science.

[142]  F. E. Chen,et al.  Regulation of DNA binding by Rel/NF-kappaB transcription factors: structural views. , 1999, Oncogene.

[143]  S. Robson,et al.  Lysophosphatidic Acid Activates Nuclear Factor Kappa B and Induces Proinflammatory Gene Expression in Endothelial Cells , 1999, Thrombosis and Haemostasis.

[144]  R. Takamiya,et al.  High mobility group A1 protein mediates human nitric oxide synthase 2 gene expression , 2008, FEBS letters.

[145]  B. Hartley‐åsp,et al.  Induction of micronuclei in the mouse. Revised timing of the final stage of erythropoiesis. , 1983, Mutation research.

[146]  M. K. Bach,et al.  Apparent antimutagenic activity of quinacrine hydrochloride in Detroit-98 human sternal marrow cells grown in culture. , 1969, Cancer research.

[147]  R. Meneghini.  Repair replication of opossum lymphocyte DNA: effect of compounds that bind to DNA. , 1974, Chemico-biological interactions.

[148]  F. Page.  Treatment of lupus erythematosus with mepacrine. , 1951, Lancet.

[149]  K. Ytrehus,et al.  Mepacrine protects the isolated rat heart during hypoxia and reoxygenation —but not by inhibition of phospholipase A2 , 1997, Basic Research in Cardiology.

[150]  A. Gasc,et al.  Genetic studies of acridine-induced mutants in Streptococcus pneumoniae. , 1978, Genetics.

[151]  M. Amelia,et al.  DNA Cleavage Induced by Photoexcited Antimalarial Drugs: A Photophysical and Photobiological Study , 2007, Photochemistry and photobiology.

[152]  J. Slaton.  Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors , 2006 .

[153]  J. Sotelo,et al.  The antimalarials quinacrine and chloroquine potentiate the transplacental carcinogenic effect of ethylnitrosourea on ependymal cells , 2006, Brain Tumor Pathology.

[154]  B. Ames,et al.  Frameshift mutagenesis in Salmonella. , 1966, Cold Spring Harbor symposia on quantitative biology.

[155]  A. J. Zeind,et al.  Mechanism of suppression of cardiac L-type Ca(2+) currents by the phospholipase A(2) inhibitor mepacrine. , 2000, European journal of pharmacology.

[156]  B. Evers,et al.  The role of NF-κB/IκB proteins in cancer: implications for novel treatment strategies , 1999 .

[157]  R. Rivlin,et al.  Enhanced growth of mammary adenocarcinoma in rats by chloroquine and quinacrine. , 1994, Cancer letters.

[158]  Haseeb Ahmad Khan,et al.  Protective effect of quinacrine on striatal dopamine levels in 6-OHDA and MPTP models of Parkinsonism in rodents , 2001, Brain Research Bulletin.

[159]  G. Goodwin,et al.  A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. , 1973, European journal of biochemistry.

[160]  M. K. Bach,et al.  The antimutagenic action of polyamines: suppression of the mutagenic action of an E. coli mutator gene and of 2-aminopurine. , 1966, Proceedings of the National Academy of Sciences of the United States of America.

[161]  R. Harris,et al.  Apical ANG II-stimulated PLA2activity and Na+flux: a potential role for Ca2+-independent PLA2. , 1997, American journal of physiology. Renal physiology.

[162]  T. Caspersson,et al.  Identification of human chromosomes by DNA-binding fluorescent agents , 2004, Chromosoma.

[163]  G. Courtois,et al.  Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. , 2006, Blood.